Canada Markets closed

PLx Pharma Inc. (PLXP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.4000+0.0600 (+2.56%)
At close: 04:00PM EDT
2.4000 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.3400
Open2.3200
Bid2.3700 x 3200
Ask2.4700 x 900
Day's Range2.2800 - 2.4500
52 Week Range1.8100 - 21.5000
Volume102,193
Avg. Volume189,351
Market Cap66.089M
Beta (5Y Monthly)4.44
PE Ratio (TTM)N/A
EPS (TTM)-3.1020
Earnings DateMar 10, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.33
  • GlobeNewswire

    PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 2022

    SPARTA, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (ref

  • GlobeNewswire

    PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions

    VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac EventsSPARTA, N. J., May 20, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury

  • Zacks

    PLx Pharma, Inc. (PLXP) Reports Q1 Loss, Lags Revenue Estimates

    PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 4.35% and 11.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?